Emergent BioSolutions (EBS) Cash from Operations Growth (3y) (2013 - 2026)
Emergent BioSolutions (EBS) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 7.32% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 27.85% |
| 10 | Emergent BioSolutions | 389.77 Mn | 228.27 Mn | 84.10 Mn | 43.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.15% |
| Dec 31, 2025 | -5.75% |
| Sep 30, 2025 | 68.56% |
| Jun 30, 2025 | 106.62% |
| Mar 31, 2025 | 33.04% |
| Dec 31, 2024 | -30.91% |
| Sep 30, 2024 | 109.57% |
| Jun 30, 2024 | 53.25% |
| Mar 31, 2024 | -142.58% |
| Dec 31, 2023 | -49.28% |
| Sep 30, 2023 | -17.07% |
| Jun 30, 2023 | -42.51% |
| Mar 31, 2023 | -73.06% |
| Dec 31, 2022 | -8.74% |
| Sep 30, 2022 | -187.93% |
| Jun 30, 2022 | 24.19% |
| Mar 31, 2022 | -33.06% |
| Dec 31, 2021 | 58.46% |
| Sep 30, 2021 | -54.22% |
| Jun 30, 2021 | -41.92% |